|
diabetes |
29 |
|
covid-19 |
25 |
|
sars-cov-2 |
25 |
|
humans |
23 |
|
adult |
21 |
|
middle aged |
21 |
|
osteoporosis |
19 |
|
type 2 diabetes |
19 |
|
female |
18 |
|
male |
18 |
|
chinese |
17 |
|
thyroid function tests |
17 |
|
aged |
16 |
|
bone mineral density |
16 |
|
obesity |
15 |
|
diabetes mellitus |
14 |
|
stroke |
14 |
|
thyroid gland |
13 |
|
microvascular complications |
12 |
|
autoimmunity |
11 |
|
bone density |
11 |
|
fatty liver disease |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
thyroiditis |
11 |
|
type 2 diabetes mellitus |
11 |
|
advanced glycation end-products |
10 |
|
atrial fibrillation |
10 |
|
body mass index |
10 |
|
epidemiology |
10 |
|
prospective studies |
10 |
|
asian-specific |
9 |
|
cancer |
9 |
|
cardiovascular complications |
9 |
|
euthyroid sick syndromes |
9 |
|
exome-chip association analysis |
9 |
|
genotype |
9 |
|
infection |
9 |
|
insulin resistance - physiology |
9 |
|
medical sciences |
9 |
|
pax4 |
9 |
|
pharmacoepidemiology |
9 |
|
primary care |
9 |
|
risk factors |
9 |
|
bronchiectasis |
8 |
|
ectopic acth syndrome |
8 |
|
interferon beta-1b |
8 |
|
misconception |
8 |
|
perception |
8 |
|
predictive value of tests |
8 |
|
prognosis |
8 |
|
qualitative |
8 |
|
smoking cessation |
8 |
|
theory of planned behaviour |
8 |
|
autoantibodies |
7 |
|
blood glucose - analysis |
7 |
|
blood pressure |
7 |
|
cardiovascular diseases |
7 |
|
case-control studies |
7 |
|
cilia |
7 |
|
complications |
7 |
|
double-blind method |
7 |
|
dpp4 inhibitor |
7 |
|
enzyme-linked immunosorbent assay |
7 |
|
fib-4 |
7 |
|
glomerular filtration rate |
7 |
|
mendelian randomization |
7 |
|
mortality |
7 |
|
nfs |
7 |
|
polymorphism, single nucleotide |
7 |
|
post–acute covid-19 syndrome |
7 |
|
risk |
7 |
|
sglt2 inhibitor |
7 |
|
statins |
7 |
|
transmission electronic microscopy |
7 |
|
adiponectin |
6 |
|
adiponectin - blood |
6 |
|
adiposity - physiology |
6 |
|
albuminuria |
6 |
|
allele |
6 |
|
animal cell |
6 |
|
anti-coagulant |
6 |
|
blood glucose - metabolism |
6 |
|
blood pressure - physiology |
6 |
|
bone metabolism |
6 |
|
c-reactive protein |
6 |
|
calcium |
6 |
|
cardiovascular disease |
6 |
|
chemicals and cas registry numbers |
6 |
|
china - epidemiology |
6 |
|
chinese medicine |
6 |
|
ciliary central microtubular orientation |
6 |
|
clinical trial |
6 |
|
clinical trials |
6 |
|
cohort studies |
6 |
|
complementary medicine |
6 |
|
diabetes & endocrinology |
6 |
|
diabetes mellitus, type 2 - blood - drug therapy |
6 |
|
diabetic nephropathy & vascular disease |
6 |
|
doac |
6 |
|
epidemiological studies |
6 |
|
follow-up studies |
6 |
|
glucose tolerance test |
6 |
|
glyburide - therapeutic use |
6 |
|
glycosylation end products, advanced - blood |
6 |
|
hypertension |
6 |
|
hypertension - blood - epidemiology |
6 |
|
hypoglycemic agents - therapeutic use |
6 |
|
lipids - blood |
6 |
|
messenger rna |
6 |
|
meta-analysis |
6 |
|
mineral metabolism |
6 |
|
nephrology |
6 |
|
obesity - blood - complications |
6 |
|
pragmatic |
6 |
|
prediction |
6 |
|
rage |
6 |
|
receptors, immunologic - blood - drug effects |
6 |
|
soluble receptor for advanced glycation end-products |
6 |
|
thiazolidinedione |
6 |
|
thiazolidinediones - therapeutic use |
6 |
|
transcription factor gata 2 |
6 |
|
vitamin d |
6 |
|
administration, inhalation |
5 |
|
aged, 80 and over |
5 |
|
aldosterone synthase deficiency |
5 |
|
androstadienes - administration & dosage |
5 |
|
asian continental ancestry group |
5 |
|
avascular necrosis |
5 |
|
bmd |
5 |
|
bone turnover markers |
5 |
|
bronchiectasis - drug therapy |
5 |
|
cholesterol - blood |
5 |
|
clinical outcomes |
5 |
|
continuous glucose monitoring |
5 |
|
diagnosis, differential |
5 |
|
drug utilization |
5 |
|
endoscopic ultrasound |
5 |
|
endothelial progenitor cells |
5 |
|
end‐ |
5 |
|
familial hypercholesterolemia |
5 |
|
follow-up |
5 |
|
forced expiratory volume - physiology |
5 |
|
fracture |
5 |
|
global healthsales |
5 |
|
glucocorticoids |
5 |
|
health preference |
5 |
|
health-related quality of life |
5 |
|
heart disease |
5 |
|
hemoglobin a, glycosylated - analysis |
5 |
|
hong kong |
5 |
|
hypoaldosteronism |
5 |
|
hypophosphatemia - etiology |
5 |
|
inhaled corticosteroid therapy |
5 |
|
insulinoma |
5 |
|
intermittent hypoxia |
5 |
|
lipase - blood |
5 |
|
lipid-modifying agents |
5 |
|
lipoproteins, hdl - blood |
5 |
|
multiple endocrine neoplasia |
5 |
|
nitric oxide |
5 |
|
nomogram |
5 |
|
paraganglioma |
5 |
|
pheochromocytoma |
5 |
|
pseudomonas aeruginosa |
5 |
|
public health |
5 |
|
radio frequency ablation |
5 |
|
risk prediction model |
5 |
|
salt-wasting |
5 |
|
sars |
5 |
|
stage renal disease |
5 |
|
succinate dehydrogenase |
5 |
|
triglyceride |
5 |
|
triglycerides - blood |
5 |
|
vertebral fracture |
5 |
|
vital capacity |
5 |
|
25-hydroxyvitamin d |
4 |
|
acth precursor |
4 |
|
acth syndrome, ectopic - complications - diagnosis |
4 |
|
adrenocorticotropic hormone - analysis |
4 |
|
alkaline phosphatase - blood |
4 |
|
alkaline phosphatase - metabolism |
4 |
|
anti-diabetic agents |
4 |
|
anti-hypertensive |
4 |
|
anti-obesity agents - therapeutic use |
4 |
|
apolipoprotein e polymorphism |
4 |
|
association |
4 |
|
atypical femoral fractures |
4 |
|
binding sites - genetics |
4 |
|
biological markers - blood |
4 |
|
bisphosphonates |
4 |
|
bone density - genetics |
4 |
|
bone health |
4 |
|
bone metastases |
4 |
|
bone neoplasms - complications - diagnosis |
4 |
|
bone neoplasms - secondary |
4 |
|
caffeine |
4 |
|
carrier proteins - blood |
4 |
|
cascade screening |
4 |
|
cdx1 |
4 |
|
cell adhesion molecules - genetics - metabolism |
4 |
|
china |
4 |
|
china - ethnology |
4 |
|
cholesterol |
4 |
|
cholesterol ester transfer proteins |
4 |
|
coffee |
4 |
|
coronary artery disease |
4 |
|
covid-19 vaccines |
4 |
|
covid‐19 |
4 |
|
cpap treatment |
4 |
|
cross-over studies |
4 |
|
cushing syndrome - etiology |
4 |
|
cushing’s syndrome |
4 |
|
cva |
4 |
|
delayed-action preparations |
4 |
|
diabetes mellitus - drug therapy |
4 |
|
diabetes mellitus type 1 |
4 |
|
diabetes mellitus, type 2 |
4 |
|
diabetes mellitus, type 2 - blood - complications |
4 |
|
diabetes mellitus, type 2 - blood - drug therapy - enzymology |
4 |
|
dietary fats - metabolism |
4 |
|
dipeptidyl-peptidase iv inhibitors |
4 |
|
dyslipidaemia |
4 |
|
enzyme inhibitors - therapeutic use |
4 |
|
epstein- barr virus |
4 |
|
falls |
4 |
|
fatty acids, nonesterified - blood |
4 |
|
forearm - abnormalities |
4 |
|
fractures, bone |
4 |
|
free fatty acids |
4 |
|
gene frequency |
4 |
|
genetic association |
4 |
|
genetic predisposition to disease |
4 |
|
giant cell tumor of bone - complications - diagnosis |
4 |
|
glucagon-like peptide-1 receptor agonists |
4 |
|
glycemic index |
4 |
|
glycogenic hepatopathy |
4 |
|
glycoproteins |
4 |
|
graves' disease |
4 |
|
herpesvirus 4, human - isolation & purification |
4 |
|
hip structure analysis |
4 |
|
hkos score |
4 |
|
homeodomain proteins - metabolism |
4 |
|
hospitalization |
4 |
|
hyperglycemia - genetics |
4 |
|
hyperlipidemias - drug therapy |
4 |
|
hyperparathyroidism - complications - diagnosis |
4 |
|
hypertriglyceridemia - blood - complications |
4 |
|
insulin - blood |
4 |
|
insulin resistance |
4 |
|
insulin sensitivity |
4 |
|
insulin-independent |
4 |
|
insulin-like growth factor i - analysis |
4 |
|
ischemic stroke |
4 |
|
lactones - therapeutic use |
4 |
|
ldl receptor |
4 |
|
ldl-c |
4 |
|
lipase inhibitor |
4 |
|
lipoproteins |
4 |
|
lipoproteins - blood |
4 |
|
lipoproteins, ldl - blood |
4 |
|
liver function tests |
4 |
|
low-density lipoprotein |
4 |
|
metabolomics |
4 |
|
metabolomics study |
4 |
|
nasopharyngeal carcinoma |
4 |
|
nasopharyngeal neoplasms - complications - diagnosis |
4 |
|
nitric oxide synthase type iii - genetics |
4 |
|
non-alcoholic fatty liver disease |
4 |
|
non-diabetic men |
4 |
|
obstructive sleep apnoea |
4 |
|
octreotide - therapeutic use |
4 |
|
osteitis deformans - blood - diagnosis - pathology - therapy |
4 |
|
osteitis deformans - diagnosis |
4 |
|
osteomalacia - etiology |
4 |
|
osteoporotic fractures - genetics - physiopathology |
4 |
|
osteosclerosis - diagnosis |
4 |
|
pancreatic tumor |
4 |
|
parathyroid hormone |
4 |
|
parathyroidectomy |
4 |
|
peptide fragments - blood |
4 |
|
periostin |
4 |
|
polymorphism, genetic |
4 |
|
postprandial lipemia |
4 |
|
postprandial period |
4 |
|
postprandial period - drug effects |
4 |
|
prevalence |
4 |
|
primary prevention |
4 |
|
protein binding - genetics |
4 |
|
reference values |
4 |
|
remnant-like lipoproteins |
4 |
|
replication |
4 |
|
serum calcium |
4 |
|
serum metabolites |
4 |
|
severity of sleep disordered breathing |
4 |
|
sleep apnea syndromes - blood - physiopathology |
4 |
|
sleep apnea, obstructive - blood - physiopathology - therapy |
4 |
|
sodium-glucose cotransporter 2 inhibitors |
4 |
|
sodium-glucose transporter 2 inhibitors |
4 |
|
sodium–glucose co-transporter type 2 inhibitors |
4 |
|
soft tissue neoplasms - complications - diagnosis |
4 |
|
somatostatin - analogs & derivatives |
4 |
|
spinal fractures - genetics - physiopathology |
4 |
|
statin |
4 |
|
threshold level |
4 |
|
trabecular bone score |
4 |
|
triglyceride-rich lipoprotein remnants |
4 |
|
validation studies |
4 |
|
vitamin d - therapeutic use |
4 |
|
vitamin d binding protein |
4 |
|
vitamin d insufficiency |
4 |
|
weight loss |
4 |
|
yolk sac tumor |
4 |
|
3t3-l1 cells |
3 |
|
absorptiometry, photon - methods |
3 |
|
acromegaly - blood |
3 |
|
acromegaly - blood - surgery |
3 |
|
acromegaly - complications - drug therapy - pathology |
3 |
|
acromegaly - drug therapy |
3 |
|
adipose tissue |
3 |
|
advanced glycation end products |
3 |
|
akap11 |
3 |
|
albuminuria - drug therapy |
3 |
|
alleles |
3 |
|
analysis of variance |
3 |
|
animals |
3 |
|
anthropometry |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic agents, hormonal - therapeutic use |
3 |
|
aorta - cytology - metabolism |
3 |
|
apob gene |
3 |
|
apolipoprotein a-i - analysis |
3 |
|
apolipoprotein a-i - metabolism |
3 |
|
apolipoprotein e |
3 |
|
asian |
3 |
|
asian continental ancestry group - genetics - statistics and numerical data |
3 |
|
body composition |
3 |
|
body fat |
3 |
|
brachial artery - physiopathology |
3 |
|
bronchiectasis - pathology |
3 |
|
c-reactive protein - metabolism |
3 |
|
calcium blood level |
3 |
|
causality |
3 |
|
cells, cultured |
3 |
|
cephalometry |
3 |
|
chinese postmenopausal women |
3 |
|
cholesterol, hdl - blood |
3 |
|
chronic disease |
3 |
|
cilia - physiology - ultrastructure |
3 |
|
codon, nonsense |
3 |
|
cross-sectional study |
3 |
|
diabetes mellitus - blood - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
diabetes mellitus - epidemiology - ethnology - therapy |
3 |
|
diabetes mellitus, type 2 - blood |
3 |
|
diabetes mellitus, type 2 - blood - diagnosis - epidemiology |
3 |
|
diabetes mellitus, type 2 - blood - physiopathology - ultrasonography |
3 |
|
diabetic nephropathy |
3 |
|
diet therapy |
3 |
|
different intervention thresholds |
3 |
|
diseases in twins - genetics |
3 |
|
dna mutational analysis - methods |
3 |
|
endothelium, vascular - cytology - physiopathology - ultrasonography |
3 |
|
estradiol - blood |
3 |
|
european continental ancestry group |
3 |
|
fatty liver |
3 |
|
fibroblast growth factor 21 |
3 |
|
follicle stimulating hormone (fsh) |
3 |
|
follicle stimulating hormone - blood |
3 |
|
fracture incidence |
3 |
|
fracture prevention |
3 |
|
frameshift mutation |
3 |
|
frax with nhanes t-score |
3 |
|
genetic predisposition to disease - ethnology - genetics |
3 |
|
genetic spectrum |
3 |
|
genetic variation - genetics |
3 |
|
germ-line mutation |
3 |
|
glucokinase - genetics |
3 |
|
glucose intolerance - blood - diagnosis - epidemiology |
3 |
|
glucose intolerance - genetics |
3 |
|
glycosylated hemoglobin a |
3 |
|
graves disease |
3 |
|
growth hormone - blood |
3 |
|
handgrip strength |
3 |
|
hong kong - epidemiology |
3 |
|
human growth hormone - blood |
3 |
|
human growth hormone - secretion |
3 |
|
hyperglycemia - blood - diagnosis - epidemiology |
3 |
|
hypoglycemic agents - administration and dosage - therapeutic use |
3 |
|
hypogonadism - blood - drug therapy |
3 |
|
insulin - administration and dosage - therapeutic use |
3 |
|
intercellular signaling peptides and proteins |
3 |
|
intercellular signaling peptides and proteins - blood |
3 |
|
interferons |
3 |
|
ldlr gene |
3 |
|
leptin - blood |
3 |
|
lipase - metabolism |
3 |
|
lipid metabolism |
3 |
|
lipoprotein glomerulopathy |
3 |
|
lipoproteins - metabolism |
3 |
|
lipoproteins, hdl - metabolism |
3 |
|
liver - enzymology |
3 |
|
losartan - therapeutic use |
3 |
|
luteinizing hormone - blood |
3 |
|
mc3t3-e1 |
3 |
|
melanoma |
3 |
|
melanoma - diagnosis - secondary - surgery |
3 |
|
menopause |
3 |
|
metabolic syndrome x - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
metastasis |
3 |
|
mice |
3 |
|
microscopy, electron, transmission |
3 |
|
microtubular defects |
3 |
|
microtubules |
3 |
|
mineralization |
3 |
|
multimorbidity |
3 |
|
multiple endocrine neoplasia type 1 - genetics |
3 |
|
mutation, missense |
3 |
|
nasal mucosa - cytology - ultrastructure |
3 |
|
nephrotic syndrome |
3 |
|
nitric oxide - biosynthesis |
3 |
|
nutrition surveys |
3 |
|
obesity - diagnosis - ethnology |
3 |
|
octreotide - administration & dosage |
3 |
|
osteogenesis |
3 |
|
osteoporosis - blood - ethnology - genetics |
3 |
|
pathogenesis |
3 |
|
pedigree |
3 |
|
pituitary |
3 |
|
pituitary neoplasms - diagnosis - secondary - surgery |
3 |
|
polymorphism |
3 |
|
polysomnography |
3 |
|
post-acute covid-19 syndrome |
3 |
|
prediabetes |
3 |
|
promoter regions, genetic - genetics |
3 |
|
protein-serine-threonine kinases - genetics |
3 |
|
proteins - metabolism - pharmacology |
3 |
|
proteinuria |
3 |
|
rankl |
3 |
|
receptors, cell surface - metabolism |
3 |
|
receptors, immunologic - blood |
3 |
|
regression analysis |
3 |
|
retrospective studies |
3 |
|
risk stratification |
3 |
|
sensitivity and specificity |
3 |
|
sglt2 inhibitors |
3 |
|
skin neoplasms - pathology - surgery |
3 |
|
sleep apnea syndromes - complications - drug therapy - pathology |
3 |
|
spirometry |
3 |
|
statin therapy |
3 |
|
statistics, nonparametric |
3 |
|
testosterone - blood - therapeutic use |
3 |
|
time factors |
3 |
|
tomography, x-ray computed |
3 |
|
total cholesterol |
3 |
|
transsphenoidal approach |
3 |
|
ubiquitin-protein ligases |
3 |
|
united states - epidemiology |
3 |
|
vaccines |
3 |
|
vasodilation |
3 |
|
waist circumference |
3 |
|
acromegaly |
2 |
|
acromegaly - blood - drug therapy |
2 |
|
administration, cutaneous |
2 |
|
adolescent |
2 |
|
affect - drug effects |
2 |
|
age of onset |
2 |
|
aging - genetics - metabolism |
2 |
|
all-cause mortality |
2 |
|
angiotensin ii receptor antagonist |
2 |
|
angiotensin receptor antagonists |
2 |
|
angiotensin-converting enzyme |
2 |
|
angiotensinogen |
2 |
|
anti-inflammatory agents - therapeutic use |
2 |
|
anticholesteremic agents - pharmacology |
2 |
|
anticholesteremic agents - therapeutic use |
2 |
|
antigens, cd36 - genetics |
2 |
|
antithyroid agents - therapeutic use |
2 |
|
apolipoproteins - blood |
2 |
|
apolipoproteins b - analysis |
2 |
|
asian continental ancestry group - genetics |
2 |
|
atherosclerosis - blood - etiology |
2 |
|
atrial natriuretic factor - genetics |
2 |
|
atrial natriuretic peptide |
2 |
|
blood coagulation - drug effects |
2 |
|
brachial artery - ultrasonography |
2 |
|
bromocriptine - therapeutic use |
2 |
|
c-peptide - blood |
2 |
|
c-reactive protein - analysis - antagonists & inhibitors |
2 |
|
carbamylation |
2 |
|
cardiovascular outcome |
2 |
|
carrier proteins - genetics |
2 |
|
centrifugation, density gradient |
2 |
|
cerebrotendinous xanthomatosis |
2 |
|
cholesterol, ldl - analysis |
2 |
|
cholesteryl ester transfer protein |
2 |
|
copper - chemistry |
2 |
|
coronary disease - epidemiology - prevention and control |
2 |
|
coronary heart disease |
2 |
|
cyanate |
2 |
|
cyp27a1 |
2 |
|
cytochrome p-450 cyp27a1 |
2 |
|
deoxyribonuclease hpaii - genetics |
2 |
|
diabetes mellitus - blood - classification - drug therapy - immunology |
2 |
|
diabetes mellitus, type 2 - blood - complications - physiopathology |
2 |
|
diabetes mellitus, type 2 - blood - immunology |
2 |
|
diabetes mellitus, type 2 - blood - physiopathology |
2 |
|
diabetes mellitus, type 2 - complications - diagnosis |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology - ultrasonography |
2 |
|
diabetes mellitus, type 2 - physiopathology |
2 |
|
diabetic ketoacidosis - blood - immunology |
2 |
|
diabetic nephropathies |
2 |
|
dihydrotestosterone - blood |
2 |
|
dinoprost - analogs & derivatives - blood |
2 |
|
disease progression |
2 |
|
dna - analysis |
2 |
|
doubling of creatinine |
2 |
|
electrophoresis, polyacrylamide gel |
2 |
|
endocrinology |
2 |
|
endothelial dysfunction |
2 |
|
endothelium, vascular - drug effects - physiopathology - ultrasonography |
2 |
|
endothelium, vascular - physiology - physiopathology |
2 |
|
endothelium, vascular - physiology - ultrasonography |
2 |
|
endothelium, vascular - physiopathology |
2 |
|
fatty acids, monounsaturated - pharmacology |
2 |
|
fibrinolysis - drug effects |
2 |
|
fibroblast growth factor-21 |
2 |
|
galectin-3 |
2 |
|
gene |
2 |
|
gene deletion |
2 |
|
gene expression regulation |
2 |
|
genetic markers |
2 |
|
genetic testing |
2 |
|
genetic variation |
2 |
|
genomewide association studies |
2 |
|
glycoxidized low-density lipoprotein |
2 |
|
graves disease - blood - drug therapy |
2 |
|
growth hormone |
2 |
|
growth hormone - blood - drug effects |
2 |
|
hdl dysfunction |
2 |
|
hemoglobin a, glycosylated - metabolism |
2 |
|
hepatic lipase |
2 |
|
heptanoic acids - therapeutic use |
2 |
|
heterozygote |
2 |
|
high-lipoprotein cholesterol |
2 |
|
histocompatibility testing |
2 |
|
hla-dr3 antigen - genetics |
2 |
|
homocysteine |
2 |
|
homocysteine - blood |
2 |
|
homozygote |
2 |
|
hong kong - ethnology |
2 |
|
hong kong chinese |
2 |
|
hormone antagonists - therapeutic use |
2 |
|
hormone replacement therapy |
2 |
|
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
2 |
|
hypercholesterolemia - blood - complications |
2 |
|
hyperhomocysteinemia - blood - complications - physiopathology |
2 |
|
hyperlipidemias - blood - drug therapy - epidemiology |
2 |
|
hyperlipidemias - complications - genetics |
2 |
|
hypertension - blood - genetics |
2 |
|
hypertension - enzymology - genetics |
2 |
|
hypogonadism - blood - drug therapy - physiopathology - psychology |
2 |
|
hypogonadism - drug therapy - metabolism |
2 |
|
hypothyroidism - blood - drug therapy - etiology |
2 |
|
incident macroalbuminuria |
2 |
|
indoles - pharmacology |
2 |
|
instrumental variables analysis |
2 |
|
insulin - therapeutic use |
2 |
|
insulin-like growth factor i - drug effects - metabolism |
2 |
|
insulin-like growth factor-i |
2 |
|
intracellular lipid |
2 |
|
kinetics |
2 |
|
linear models |
2 |
|
lipid peroxidation |
2 |
|
lipid-modifying therapy |
2 |
|
lipoprotein |
2 |
|
lipoprotein lipase |
2 |
|
lipoprotein lipase - blood |
2 |
|
lipoproteins, ldl - blood - drug effects |
2 |
|
lipoproteins, ldl - physiology |
2 |
|
liver - enzymology - metabolism |
2 |
|
longitudinal studies |
2 |
|
macrophage |
2 |
|
macrophages - chemistry |
2 |
|
masturbation - epidemiology |
2 |
|
microalbuminuria |
2 |
|
microsomal triglyceride transfer protein |
2 |
|
monocytes |
2 |
|
myeloperoxidase |
2 |
|
myocardial infarction - enzymology - genetics |
2 |
|
nandrolone - adverse effects - analogs and derivatives - therapeutic use |
2 |
|
nitroglycerin - pharmacology |
2 |
|
normocholesterolemic tendon xanthomas |
2 |
|
novel splicing mutation |
2 |
|
obstructive sleep apnea |
2 |
|
oxidative stress |
2 |
|
peptidyl-dipeptidase a - genetics |
2 |
|
placebos |
2 |
|
point mutation |
2 |
|
polymerase chain reaction |
2 |
|
polymorphism, restriction fragment length |
2 |
|
progression of renal failure |
2 |
|
pyrroles - therapeutic use |
2 |
|
radioimmunoassay |
2 |
|
receptors, immunologic - genetics |
2 |
|
receptors, scavenger |
2 |
|
renal fibrosis |
2 |
|
reverse transcriptase polymerase chain reaction |
2 |
|
rna splicing |
2 |
|
scavenger receptor |
2 |
|
scavenger receptors, class a |
2 |
|
scavenger receptors, class b |
2 |
|
sexual behavior - drug effects |
2 |
|
sleep apnea, obstructive - blood - complications |
2 |
|
small dense low density lipoprotein |
2 |
|
smoking |
2 |
|
steroid hydroxylases - genetics |
2 |
|
sterol 27-hydroxylase |
2 |
|
testosterone - administration & dosage - metabolism |
2 |
|
thyroid diseases - blood |
2 |
|
triglycerides - antagonists & inhibitors - blood |
2 |
|
uraemia |
2 |
|
vasodilation - drug effects |
2 |
|
vasodilation - physiology |
2 |
|
vasodilator agents - pharmacology |
2 |
|
xanthomatosis, cerebrotendinous - genetics |
2 |
|
absorptiometry, photon - methods - standards |
1 |
|
acute disease |
1 |
|
acute-phase proteins - metabolism |
1 |
|
acute-phase reaction - etiology |
1 |
|
acute-phase response |
1 |
|
adenosine |
1 |
|
adenosine - analogs & derivatives - metabolism - pharmacology |
1 |
|
adenosine diphosphate - antagonists & inhibitors - pharmacology |
1 |
|
adenosine receptors |
1 |
|
adenosine triphosphate binding cassette transporters |
1 |
|
adenosine-5'-(n-ethylcarboxamide) |
1 |
|
adrenal adenoma |
1 |
|
adrenal hyperplasia |
1 |
|
advanced glycation end products (ages) |
1 |
|
advanced glycation end-product (age) |
1 |
|
aequorin - metabolism |
1 |
|
aggregation |
1 |
|
albuminuria - blood |
1 |
|
albuminuria - blood - metabolism |
1 |
|
antihypertensive agents - therapeutic use |
1 |
|
antioxidants - metabolism |
1 |
|
aorta - enzymology |
1 |
|
apolipoprotein a-i - pharmacology |
1 |
|
apolipoprotein ai |
1 |
|
apolipoproteins b - metabolism |
1 |
|
apolipoproteins e - blood |
1 |
|
aryldialkylphosphatase - metabolism |
1 |
|
asia - epidemiology |
1 |
|
asian continental ancestry group - classification - statistics and numerical data |
1 |
|
atorvastatin |
1 |
|
atp |
1 |
|
atp binding cassette transporters |
1 |
|
atp-binding cassette transporter a1 |
1 |
|
atp-binding cassette transporters - biosynthesis - blood - genetics |
1 |
|
atp-binding cassette transporters - blood - genetics - metabolism |
1 |
|
atp-binding cassette transporters - metabolism |
1 |
|
awareness |
1 |
|
binding sites |
1 |
|
biological transport |
1 |
|
biomarker |
1 |
|
blood platelets - chemistry - physiology |
1 |
|
blood platelets - drug effects |
1 |
|
blood platelets - drug effects - metabolism - physiology |
1 |
|
blood platelets - drug effects - physiology |
1 |
|
blood platelets - enzymology |
1 |
|
blotting, western - methods |
1 |
|
body constitution |
1 |
|
body weight |
1 |
|
body weight - ethnology |
1 |
|
body weight gain |
1 |
|
brachial artery - physiopathology - ultrasonography |
1 |
|
c-reactive protein - analysis - pharmacology |
1 |
|
c-reactive protein - antagonists & inhibitors - drug effects - metabolism |
1 |
|
calcium - blood |
1 |
|
calcium - metabolism |
1 |
|
camp |
1 |
|
carbohydrate intake |
1 |
|
cardiovascular diseases - etiology |
1 |
|
carrier proteins - metabolism |
1 |
|
cat diseases - drug therapy |
1 |
|
catecholamines - analysis |
1 |
|
cats |
1 |
|
cell line, tumor |
1 |
|
cell membrane - metabolism |
1 |
|
cholesterol - blood - metabolism |
1 |
|
cholesterol efflux |
1 |
|
cholesterol ester transfer proteins - antagonists & inhibitors |
1 |
|
cholesterol esters - metabolism |
1 |
|
cholesterol, hdl - deficiency |
1 |
|
cholesterol, hdl - metabolism |
1 |
|
cholesterol, ldl - blood |
1 |
|
cholesterol, ldl - metabolism |
1 |
|
cholestyramine |
1 |
|
cholestyramine resin - pharmacology |
1 |
|
chylomicrons - blood |
1 |
|
clinical prediction |
1 |
|
collagen |
1 |
|
collagen - pharmacology |
1 |
|
combined modality therapy |
1 |
|
congresses as topic |
1 |
|
coronary artery |
1 |
|
coronary artery disease - blood - etiology |
1 |
|
coronary disease - blood - diagnosis |
1 |
|
coronary disease - etiology |
1 |
|
creatinine clearance |
1 |
|
cyclic amp |
1 |
|
cyclic amp - blood |
1 |
|
dense ldl |
1 |
|
diabetes mellitus - drug therapy - veterinary |
1 |
|
diabetes mellitus, type 1 - complications - metabolism |
1 |
|
diabetes mellitus, type 2 - blood - ethnology |
1 |
|
diabetes mellitus, type 2 - blood - genetics |
1 |
|
diabetes mellitus, type 2 - blood - metabolism |
1 |
|
diabetes mellitus, type 2 - blood - physiopathology - therapy |
1 |
|
diabetes mellitus, type 2 - complications - immunology |
1 |
|
diabetes mellitus, type 2 - diagnosis - drug therapy |
1 |
|
diabetes mellitus, type 2 - drug therapy |
1 |
|
diabetes mellitus, type 2 - enzymology - genetics - physiopathology |
1 |
|
diabetes mellitus, type 2 - metabolism |
1 |
|
diabetic angiopathies - blood - epidemiology - physiopathology |
1 |
|
diabetic diet |
1 |
|
diabetic nephropathies - blood |
1 |
|
diabetic nephropathies - blood - physiopathology |
1 |
|
diabetic nephropathies - drug therapy |
1 |
|
diabetic nephropathies - metabolism |
1 |
|
diabetic retinopathy - blood - complications - metabolism |
1 |
|
dietary fats |
1 |
|
dyslipidemia |
1 |
|
dyslipidemias - drug therapy - epidemiology - etiology - therapy |
1 |
|
eating - physiology |
1 |
|
end-stage renal disease |
1 |
|
endothelial cells - metabolism |
1 |
|
endothelial lipase |
1 |
|
endothelium, vascular - enzymology |
1 |
|
endothelium, vascular - physiopathology - ultrasonography |
1 |
|
england |
1 |
|
enzyme-linked immunosorbent assay - methods |
1 |
|
epoprostenol - pharmacology |
1 |
|
familial hypercholesterolaemia |
1 |
|
fasting |
1 |
|
fasting - blood |
1 |
|
financial management - economics |
1 |
|
forskolin - pharmacology |
1 |
|
gene expression |
1 |
|
glycation end products |
1 |
|
glycosylation |
1 |
|
glycoxidized ldl |
1 |
|
gtp-binding proteins - physiology |
1 |
|
hdl |
1 |
|
hepatocytes - metabolism |
1 |
|
high density lipoprotein |
1 |
|
high density lipoprotein cholesterol |
1 |
|
homeostasis model assessment index |
1 |
|
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology |
1 |
|
hyperlipoproteinemia type ii - blood |
1 |
|
hyperlipoproteinemia type ii - blood - enzymology |
1 |
|
hyperlipoproteinemia type ii - blood - physiopathology |
1 |
|
hyperlipoproteinemia type ii - metabolism |
1 |
|
hypertriglyceridaemia |
1 |
|
hypertriglyceridemia |
1 |
|
hypertriglyceridemia - blood - physiopathology |
1 |
|
hypertriglyceridemia - complications - epidemiology - therapy |
1 |
|
hypertriglyceridemia - complications - genetics - metabolism - therapy |
1 |
|
hypoglycemic agents - administration & dosage - therapeutic use |
1 |
|
hypolipidemic agents - pharmacology |
1 |
|
hypolipidemic agents - therapeutic use |
1 |
|
immunoassay |
1 |
|
inflammation |
1 |
|
inositol 1 |
1 |
|
inositol 1,4,5 trisphosphate |
1 |
|
inositol 1,4,5-trisphosphate - metabolism |
1 |
|
insulin |
1 |
|
insulin - administration & dosage - therapeutic use |
1 |
|
insulin - blood - secretion |
1 |
|
insulin secretion |
1 |
|
intravascular ultrasound |
1 |
|
islets of langerhans - secretion |
1 |
|
lectin-like oxidized low density lipoprotein receptor |
1 |
|
lectin-like oxidized low density lipoprotein receptor-1 (lox-1) |
1 |
|
leukocytes, mononuclear - metabolism |
1 |
|
lipase - blood - genetics - metabolism |
1 |
|
lipase - genetics - metabolism |
1 |
|
lipoprotein lipase - metabolism |
1 |
|
lipoproteins, hdl - drug effects - metabolism |
1 |
|
lipoproteins, ldl - metabolism |
1 |
|
liver - metabolism |
1 |
|
low density lipoprotein subfractions |
1 |
|
lung neoplasms - drug therapy |
1 |
|
lymphangioleiomyomatosis - drug therapy |
1 |
|
macrophages - metabolism |
1 |
|
mammalian target of rapamycin (mtor) |
1 |
|
medical staff, hospital |
1 |
|
medroxyprogesterone - administration & dosage |
1 |
|
membrane proteins - blood |
1 |
|
membrane proteins - blood - pharmacology |
1 |
|
metabolic syndrome |
1 |
|
metabolic syndrome x - complications - epidemiology - therapy |
1 |
|
models, biological |
1 |
|
multivariate analysis |
1 |
|
nephropathy |
1 |
|
niacin - pharmacology |
1 |
|
non-insulin-dependent diabetes mellitus |
1 |
|
noradrenaline |
1 |
|
nε-(carboxymethyl)lysine |
1 |
|
obesity - classification - diagnosis - ethnology |
1 |
|
orphan nuclear receptors - agonists |
1 |
|
oxidized ldl |
1 |
|
oxysterols |
1 |
|
peritoneal dialysis |
1 |
|
peroxisome proliferator-activated receptors - agonists |
1 |
|
phosphatidylcholines - blood |
1 |
|
phospholipid transfer protein |
1 |
|
phospholipid transfer proteins |
1 |
|
phospholipid transfer proteins - blood |
1 |
|
phospholipid transfer proteins - blood - pharmacology |
1 |
|
phosphoric diester hydrolases - blood |
1 |
|
platelet activation - physiology |
1 |
|
platelet aggregation |
1 |
|
platelet aggregation - drug effects |
1 |
|
platelet aggregation - drug effects - physiology |
1 |
|
platelet aggregation inhibitors - pharmacology |
1 |
|
platelet. |
1 |
|
platelets |
1 |
|
postprandial lipaemia |
1 |
|
postprandial lipoprotein metabolism |
1 |
|
pre-β1 hdl |
1 |
|
primary aldosteronism |
1 |
|
progesterone congeners - administration & dosage |
1 |
|
proinsulin - blood |
1 |
|
proinsulin - blood - secretion |
1 |
|
protein precursors - blood - secretion |
1 |
|
proteinuria - blood - metabolism |
1 |
|
quinolines |
1 |
|
rabbits |
1 |
|
receptors |
1 |
|
receptors, immunologic - blood - genetics |
1 |
|
receptors, purinergic - metabolism |
1 |
|
remodeling index |
1 |
|
resistance |
1 |
|
reverse cholesterol transport |
1 |
|
risk factor |
1 |
|
rna, messenger - analysis - metabolism |
1 |
|
rna, messenger - blood - genetics |
1 |
|
rna, messenger - genetics |
1 |
|
saline infusion test |
1 |
|
scavenger receptor class b type i |
1 |
|
scavenger receptors, class b - biosynthesis - blood - genetics |
1 |
|
scavenger receptors, class b - blood - metabolism |
1 |
|
scavenger receptors, class b - metabolism |
1 |
|
scavenger receptors, class e - blood |
1 |
|
scavenger receptors, class e - metabolism |
1 |
|
serum cholesterol efflux capacity |
1 |
|
sex characteristics |
1 |
|
sex factors |
1 |
|
signal transduction |
1 |
|
signal transduction - drug effects |
1 |
|
small |
1 |
|
small dense ldl |
1 |
|
solubility |
1 |
|
soluble receptor for advanced glycation end product |
1 |
|
soluble receptor for advanced glycation end-product (srage) |
1 |
|
soluble receptors |
1 |
|
stroke - blood - diagnosis |
1 |
|
thiazolidinediones - pharmacology |
1 |
|
travel |
1 |
|
treatment outcome |
1 |
|
triglycerides - metabolism |
1 |
|
trisphosphate |
1 |
|
ultracentrifugation |
1 |
